PLx Pharma Inc. PLXP Cash Flow

Plx pharma inc. (PLXP)

CashFlow / TTM

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14	Dec'13	Sep'13	Jun'13	Mar'13
CASH FLOWS FROM OPERATING ACTIVITIES
Net income (loss)
-8,147	-20,502	-15,555	-20,684	-14,940	896	-9,934	-10,308	-8,941	-15,346	-8,916	-6,199	-515	-4,905	-8,955	-12,892	-20,372	-18,742	-16,512	-15,336	-15,224	-13,580	-12,559	-9,707	-6,150	-4,013	0	0	0
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Depreciation and amortization
134	158	182	206	222	200	162	116	63	29	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Stock-based compensation
1,082	875	679	666	626	841	1,041	1,750	1,718	1,624	2,016	1,630	1,306	2,471	2,347	2,320	2,985	3,275	3,178	3,052	2,966	1,418	1,688	1,408	1,077	1,077	0	0	0
Amortization of debt discounts and issuance costs
186	215	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Non-cash interest expense
-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Non-cash interest expense
-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Change in fair value of warrant liability
-6,615	5,710	1,893	7,801	3,445	-12,705	-5,652	-6,313	-9,058	-633	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Provision for obsolete inventory
-	-	-	-	-	770	1,090	795	783	319	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Share-Based Payments to Vendors
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-
Share-Based Payments to Vendors
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	169	148	450	562	550	492	123	0	0	0
Amortization of short-term investment interest income
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-
Changes in operating assets and liabilities:
Accounts receivable
-13	0	-41	66	-60	-1	-15	-253	72	14	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Inventory
-	-	-	-	-	524	717	400	493	449	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Prepaid expenses and other assets
-53	-152	402	-191	-426	109	-484	96	629	223	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Vendor deposits
-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Right of use assets
0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Prepaid expenses
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-22	-97	-25	26	21	64	-83	74	127	163	212	39	0	0	0
Security Deposit
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-
Accounts payable and accrued liabilities
156	448	570	1,003	-186	-194	-44	91	78	-109	344	97	1,255	633	1,078	687	171	345	-493	345	9	559	1,089	471	490	538	0	0	0
Accrued bonuses
-156	118	152	207	166	198	-1,528	-1,779	-1,976	-1,434	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Accrued interest
133	166	192	212	224	225	223	254	215	229	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other current and long-term liabilities
0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Accrued interest - related parties
-	-	-	-	-	-	-	-	-	13	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other current and long-term liabilities
-	-	-	-	-	-	-	190	196	201	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net cash used in operating activities
-13,160	-12,659	-11,309	-9,551	-9,054	-9,499	-12,907	-13,187	-14,896	-13,306	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Note Receivable from advance to PLx Pharma, Inc.
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-
CASH FLOWS FROM INVESTING ACTIVITIES
Net cash used in operating activities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-9,494	-16,626	-14,592	-13,474	-11,835	-12,066	-11,276	-9,281	-7,373	-4,183	-2,194	0	0	0
Purchases of property and equipment
237	241	145	2	394	654	993	1,112	732	537	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net cash used in investing activities
-225	-230	-134	9	-394	-654	-993	-1,112	11,043	11,238	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
CASH FLOWS FROM FINANCING ACTIVITIES
Net proceeds from issuance of convertible Series A preferred stock
-	13,661	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Repayments of term loan
3,750	3,125	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from Short-term Investments
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-
Purchase of Short-term Investments
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-
Net cash provided by investing activities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from issuance of convertible notes payable
-	-	-	-	-	-	-	-	-	460	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from issuance of convertible notes payable - related parties
-	-	-	-	-	-	-	-	-	108	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from Dipexium note
-	-	-	-	-	-	-	-	-	2,000	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net cash (used in) provided by financing activities
-1,646	12,640	0	0	0	-	-	-	-	26,412	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from issuance of Common Stock, net of issuance costs
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	34,455	0	0	0	-	-	-	-
Proceeds from Private Placement Offerings, net of issuance costs
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	4,598	0	0	0
Net cash provided by financing activities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	34,455	35,392	36,811	38,161	4,598	0	0	0
Net Decrease In Cash and Cash Equivalents
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-
NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS
-15,032	-248	1,972	3,331	3,900	-10,154	-13,901	-7,154	19,992	24,345	0	0	0	-	-	-	-	-	-	-3,954	-12,066	23,179	26,111	29,437	33,977	2,404	0	0	0
SUPPLEMENTAL INFORMATION
Income taxes
-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest
513	600	660	689	689	671	653	521	354	195	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NON-CASH INVESTING AND FINANCING TRANSACTIONS
Property and equipment included in accounts payable
-	-	-	-	-	-	-	-	0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred financing costs included in accounts payable and accrued liabilities
0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Preferred stock beneficial conversion feature and dividends
1,250	13,750	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Value of common shares issued to vendor for services
-	45	67	90	90	90	90	90	82	60	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-